Clinical Trials Logo

Filter by:
NCT ID: NCT04043429 Completed - Clinical trials for Brain Injuries, Traumatic

Restoration vs. Compensation in Neurovisual Rehabilitation of Visual Field Defects

Start date: January 2003
Phase: Phase 2
Study type: Interventional

Visual field defects (VFD) are a frequent effect of cerebral lesions especially after posterior cerebral artery stroke. The present study was conducted to compare effects of vision restoration training (VRT) and compensation training (Visual Exploration Training, VET) on visual field performance.

NCT ID: NCT04042792 Completed - Rheumatic Diseases Clinical Trials

Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate

ADA in PiRD
Start date: September 26, 2019
Phase:
Study type: Observational

This study is to assess standardized Adalimumab (ADA) concentrations in Pediatric inflammatory rheumatic diseases (PiRD) patients treated with ADA for ≥ 12 weeks with and without concomitant methotrexate (MTX) therapy and to assess peak and trough ADA concentrations in ADA naïve patients after first ADA administration with and without MTX (pre-phase).

NCT ID: NCT04041284 Completed - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Start date: September 13, 2019
Phase: Phase 4
Study type: Interventional

The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg sc of fremanezumab in adult participants with migraine and MDD on the reduction of MDD symptoms, responder rates in monthly migraine days, improving quality of life, improving disability, and the safety and tolerability of monthly 225 mg sc and quarterly 675 mg sc fremanezumab in adult participants with migraine and MDD. The total duration of participant participation in the study is planned to be approximately 28 weeks.

NCT ID: NCT04039503 Completed - Type 2 Diabetes Clinical Trials

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

SURPASS-5
Start date: August 30, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications. The study will last approximately 47 weeks and may include about 23 visits.

NCT ID: NCT04039113 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Tezepelumab COPD Exacerbation Study

COURSE
Start date: July 30, 2019
Phase: Phase 2
Study type: Interventional

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT ID: NCT04039074 Completed - Clinical trials for Stress, Psychological

Effects of Yoga and Relaxation on Stress and Quality of Life

Start date: July 29, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to measure the effects of three stress reduction methods on patients with stress and stress associated complaints.

NCT ID: NCT04038359 Completed - Clinical trials for Indolent Non-Hodgkin Lymphoma

A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma

TEMPO
Start date: September 24, 2019
Phase: Phase 2
Study type: Interventional

This study will examine the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.

NCT ID: NCT04037501 Completed - Dementia Clinical Trials

Effectiveness of a Care Management System to Reduce Unmet Needs of Informal Caregivers of People With Dementia

GAIN
Start date: October 9, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to test the effectiveness of a computer assisted care management system to identify and reduce unmet needs for and to improve quality of life of informal caregivers of people with dementia.

NCT ID: NCT04035733 Completed - Clinical trials for Bullous Pemphigoid (BP)

rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

Start date: September 25, 2018
Phase: Phase 2
Study type: Interventional

Bullous pemphigoid (BP) is the most common of the autoimmune blistering skin diseases in Western Europe. [Joly 2012]The study will recruit the new onset or relapsing mild to moderate BP patients. The study population will consist of patients above the age of 18 years with an active episode of BP, confirmed by inclusion and exclusion criteria and who, in the opinion of the Investigator, would benefit from treatment with rVA576. Recombinant rVA576 is a small protein complement C5 and LTB4 inhibitor, which prevents the cleavage of C5 by C5 convertase and thereby inhibits generation of C5b-9 the membrane attack complex (MAC), as well as preventing the release of the anaphylatoxin C5a. rVA576 is effective in inhibiting terminal complement activity irrespective of the activating pathway (classical, lectin or alternative). This Phase IIa open-label single-arm study will evaluate the safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid patients

NCT ID: NCT04035226 Completed - Multiple Myeloma Clinical Trials

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

LocoMMotion
Start date: August 2, 2019
Phase:
Study type: Observational

The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).